Research Papers:

IL-2 augments the therapeutic efficacy of adoptively transferred B cells which directly kill tumor cells via the CXCR4/CXCL12 and perforin pathways

Yang Xia, Huimin Tao, Yangyang Hu, Quanning Chen, Xin Chen, Leiming Xia, Li Zhou, Yi Wang, Yangyi Bao, Shiang Huang, Xiubao Ren, Steven K. Lundy, Fu Dai, Qiao Li _ and Alfred E. Chang

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:60461-60474. https://doi.org/10.18632/oncotarget.11124

Metrics: PDF 2531 views  |   HTML 2689 views  |   ?  


Yang Xia1,2,*, Huimin Tao1,3,8,*, Yangyang Hu1,3,*, Quanning Chen1,4,*, Xin Chen1,5, Leiming Xia1,2, Li Zhou1,6, Yi Wang2, Yangyi Bao2, Shiang Huang3, Xiubao Ren6, Steven K. Lundy7, Fu Dai2,**, Qiao Li1,**, Alfred E. Chang1,**

1Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA

2The No.1 People’s Hospital of Hefei, Hefei, China

3Hubei Province Stem Cell Research & Appling Center, Wuhan Union Hospital, Wuhan, China

4Department of General Surgery, Tongji Hospital of Tongji University, Shanghai, China

5Department of Oncology, Wuhan University, Renmin Hospital, Wuhan, China

6Department of Biotherapy, Tianjin University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key laboratory of Cancer Immunology and Biotherapy, Tianjin, China

7Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA

8Current address: Fuda Cancer Hospital, Jinan University School of Medicine and Fuda Cancer Institute, Guangzhou, China

*These authors have contributed equally to this work

**Joint senior authors

Correspondence to:

Qiao Li, email: [email protected]

Alfred E. Chang, email: [email protected]

Fu Dai, email: [email protected]

Keywords: B cells, adoptive immunotherapy, IL-2, CXCR4/CXCL12, perforin

Abbreviations: TDLN, tumor-draining lymph node; CM, complete medium; s.c., subcutaneous; i.v., intravenously; i.p., intraperitoneal

Received: December 06, 2015    Accepted: July 26, 2016    Published: August 09, 2016


We previously reported that antitumor B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10. In this study, we defined additional mechanisms involved in B cell antitumor immunity. Administration of IL-2 significantly augmented the therapeutic efficacy of adoptively transferred tumor-draining lymph node (TDLN) B cells which express IL- 2R. Culture supernatant of purified B splenocytes harvested from the mice that received adoptive transfer of 4T1 TDLN B cells plus IL-2 administration produced larger amounts of IgG which bound to 4T1, resulting in 4T1 lysis. Furthermore, we detected CXCR4 expression on 4T1 TDLN B cells, and 4T1 tumor cells produced its ligand CXCL12. Transwell experiments demonstrated the chemoattraction of CXCR4-expressing 4T1 TDLN B cells towards CXCL12- producing 4T1 cells. Blockade of CXCR4 using a CXCR4-specific inhibitor, AMD3100, significantly reduced the killing of 4T1 tumor cells by 4T1 TDLN B cells. Blockade of FasL and CXCR4 concurrently inhibited B cell-mediated direct killing of tumor cells in an additive manner, indicating that both Fas/FasL and CXCL12/CXCR4 pathways are involved in the direct killing of 4T1 cells by 4T1 TDLN B cells. TDLN B cells produced perforin. Additional transwell experiments showed that effector B cells could directly kill tumor cells in cell-cell contact via the Fas/FasL and CXCR4/CXCL12 pathways as well as perforin, while without cell contact, perforin secreted by B cells led to tumor cell cytotoxicity. These findings underscore the diversity of function by which B cells can play an important role in the host immune response to tumor.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11124